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Abstract. Today the growth of medical devices and mobile medical applications is 
increasing enormously thanks to the efficiency and enhancement of new technology. 
When it comes to mobile medical apps, developers need to understand what is re-
quired when a mobile application fulfils the definition of a medical device. Such appli-
cations have to be developed in compliance with medical device regulations. This 
can be a challenge for mobile medical application developers as medical device 
software is normally developed in a manner that will also ensure the production of 
regulatory documentation that is essential to market such devices. In this journal pa-
per we identify the key criteria for a mobile medical application development frame-
work and describe how the results were collected through performing a Medical De-
vice Software Development workshop. Furthermore, we describe how MDevSPICE® 
together with an agile software development approach can be tailored to support a 
mobile medical applications development framework. We detail one of the key criteria 
for mobile medical application development framework – traceability.  
Keywords: Medical Device, Medical Device Software, Mobile Application, 
Mobile Medical App, Traceability, TAIF model. 
1 Introduction 
Today, medical device (MD) software systems, including mobile medical apps 
(MMA), play an important role in our lives. MD software, according to the FDA defini-
tion, is a: “software system that has been developed for the purpose of being incorpo-
rated into the medical device being developed or that is intended for use as a medi-
cal device in its own right” [1]. However, a MMA is “a mobile app that meets the defi-
nition of device in section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C 
Act) 4; and either is intended to be used as an accessory to a regulated medical de-
vice or to transform a mobile platform into a regulated medical device” [2]. “If a mobile 
app is intended for use in performing a medical device (MD) function (i.e. for diagno-
sis of disease or other conditions, or the cure, mitigation, treatment, or prevention of 
disease) it is a medical device” [2]. 
Given the safety-critical nature of MDs, standards are in place to ensure the safety of 
these devices. In order to market a MD, it is mandatory to satisfy the regulatory re-
quirements within that particular region. Previously, the authors developed 
MDevSPICE® which contains all the MD software development best practices [3] and 
most of the standards in one place. This will be discussed in more detail further in the 
paper as by tailoring MDevSPICE® for MMAs - we envisage developers using it as 
their main development approach for MMAs. 
 
1.1 Problem Statement 
The challenge that MMA software development companies face when they want to 
market an app is the adherence to the large number of regulatory requirements spec-
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ified in various international standards. In order to help these companies better pre-
pare for demanding and costly regulatory audits alongside the development process, 
we propose to develop a MMA development framework. This framework would ease, 
assist the development process of an app and facilitate the collection of all regulatory 
requirements by guiding developers from the initial requirements gathering right 
through to the finished product. 
Within this paper we discuss how MMA development with an agile approach may be 
introduced into MDevSPICE® and finally create a MMA development framework that 
would comply with all the regulations and allow developers to successfully market 
their application [4]. 
Section II, looks at the different MD regulations and classifications for MD and MMA. 
In Section III, we describe MDevSPICE®. In Section IV, we describe the methodology 
adopted to develop the MMA development framework and we describe the workshop 
that was performed to discuss the different software development approaches for MD 
software. In Section V, we focus on one of the MMA development framework criteria 
that emerged from the workshop– traceability. We look at its benefits and barriers, 
and describe the TAIF model that was developed by some of the authors and vali-
dated to assist MD companies. The paper concludes with details of our future work in 
Section VI. 
2 Medical Device Regulations 
The largest global bodies responsible for issuing and managing MD regulations are 
the FDA in the US and the European Commission in the EU.  
• The FDA issues the regulation through a series of official channels, including 
the Code of Federal Regulation (CFR) Title 21, Chapter I, Subchapter H, Part 
820 [5].  
• In the EU, the corresponding regulation is outlined in a number of directives: 
the general Medical Device Directive (MDD) 93/42/EEC [6]; the Active Im-
plantable MDD (AIMDD) 90/385/EEC [7]; and the In-vitro Diagnostic (IVD) 
MDD 98/79/EC [8] - all three of which have been amended by 2007/47/EC [9]. 
2.1 Medical Device Classification 
The safety classifications for MDs depends upon the particular geographical region, 
the two that we refer to are the US and Europe. The MD safety classification relates 
to the clinical safety of the device. 
There are three MD safety classifications within the US: Class I, Class II and Class 
III.  
• Class I devices, such as a thermometer are not intended to support or sustain 
human life, and may not present an unreasonable risk of harm.  
• Class II devices, such as a powered wheelchair could cause damage or harm 
to humans.  
• Class III devices, such as an implantable pacemaker are usually those that 
support or sustain human life, and are of significant importance in the preven-
tion of human health impairment.  
In the EU, Class I corresponds to Class I in the US, with Class IIa and IIb corre-
sponding to Class II in the US, and Class III to Class III in the US. 
2.2 Medical Device Software Regulations 
Within the safety-critical domains it is important to have a Quality Management Sys-
tem (QMS) in place. For example, the QMS required to meet the regulatory require-
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ments of the MD domain in the EU is ISO 13485 [10]. ISO 13485 is a specialization 
of ISO 9001 [11] for the MD domain. QMS requirements need to be adhered to in or-
der to market a MD anywhere in the world. As ISO 13485 does not target software 
requirements, it can be used in conjunction with IEC 62304 [12] to support the safe 
design and maintenance of MD software. IEC 62304 is a critical standard for MD 
software developers as it is the only standard that provides recommendations for MD 
software implementations based on the worst case scenario of software failure caus-
ing hazards. For general MD risk management, IEC 62304 is used in conjunction with 
ISO 14971 [13] and IEC 80002-1 [12]. IEC 80002-1 provides guidance on the appli-
cation of ISO 14971 for software development. 
IEC 62304 considers a MD to include software as opposed to the being a complete 
MD system in its own right. The system or product level requirements are not includ-
ed within IEC 62304 but instead within the MD product standard IEC 60601-1 [12]. 
Due to the increasing importance of usability of devices within the MD industry, or-
ganizations should also adhere to the MD usability engineering process requirements 
outlined in IEC 62366 [15]. 
Standalone software systems (such as MMAs) may be defined as a MD in their own 
right, due to an amendment to the MDDs [9]. However, until recently international MD 
standards did not address standalone software as a MD. To address this IEC FDIS 
82304-1 [15] will soon be published. IEC FDIS 82304-1 applies to the safety of health 
software that is designed to operate on general purpose IT platforms intended to be 
placed on the market without dedicated hardware, e.g., tablet and phone applica-
tions. Therefore, IEC FDIS 82304-1 will be applicable to MMAs. 
If the company is planning to market a MD in the US, they need to register their 
product with the FDA. The FDA has issued an overview of their guidance documents 
for developers of MD software [16]. There are four guidance documents: the FDA 
Guidance on Premarket Submissions [17]; the FDA Guidance on Off-The-Shelf Soft-
ware Use in Medical Devices [18]; the FDA General Principles of Software Validation 
[19]; and Guidance on MMAs [1] to provide clarity for MMA developers in terms of 
what types of applications will be regulated and how. 
Whenever companies developing MD software wish to market a device they must 
adhere to a large number of regulatory requirements and international standards. In 
the case of MMAs meeting the definition of a MD, they have to comply with the same 
regulations as a MD. In order to reduce the demanding and costly overhead associ-
ated with preparing for regulatory audits, we developed MDevSPICE®. MDevSPICE® 
integrates the software requirements from all the above mentioned international MD 
standards and guidance documents with generic software development best practic-
es into a single reference source. This reference source may then be used to assess 
the capability of an organization’s MD software processes. 
2.2.1 Medical Device Software Classifications 
IEC 62304:2006 [12] describes MD software lifecycle processes and outlines soft-
ware safety classification, based on the worst possible consequence in the case of a 
software failure. In the case of failure of software that is of safety Class A no injury or 
damage to health of a patient can occur. When software of safety class B fails, injury 
may occur but it is not serious or life-threatening. Class C is of the highest risk and in 
the case of failure of such software death or serious injury can happen. Depending 
on the functionality of software within the MD, the software safety classification may 
vary from the overall MD safety class. When software is of critical functionality of the 
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MD, it will carry the same classification as the device, i.e. Class C software in Class 
III device. 
 
2.3 Mobile Medical App Types 
Both US and Europe have released guidelines “to support developers and manufac-
turers ensure public safety” [20]. 
In September 2013, the FDA in the US issued a Final Guidance on Mobile Medical 
Applications [1]. The FDA categorized MA into three categories depending on their 
risk to a human in case of its failure:  
• (1) Those apps meeting the definition of a MD and “either is intended to be 
used as an accessory to a regulated MD; or to transform a mobile platform into 
a regulated MD” [1], therefore “are the focus of FDA’s regulatory oversight” [1]. 
These mobile apps pose high risk to a human in case of its failure – i.e. injury 
or death. An example of an app for this category would be  one that regulates 
infusion pump settings;  
• (2) Those apps meeting the definition of a MD, however, through posing a low 
risk to a human in case of its failure, the FDA intends to exercise enforcement 
discretion [1]. For example, an app that helps an asthmatic to track their inhal-
er usage; 
• (3) The third category includes all apps that do not meet the definition of a MD, 
therefore the FDA does not regulate them. For example, an app that educates 
patient or tracks their fitness progression. To sum it up, if a mobile app cannot 
in any way harm a human, the FDA will not subject it to regulations. 
In Europe, in January 2012, MEDDEV 2.1/6 was published to provide guidelines on 
stand-alone software development for MMAs [21]. In order to market an app as a 
MMA, a CE Mark is required indicating that the requirements of either the MDD or the 
IVDD have been fulfilled. 
3 MDevSPICE® 
MDevSPICE® was designed to assist manufacturers to develop MD software through 
following a traditional waterfall model or V-model lifecycle model. Such development 
lifecycles are very rigid, prescribed and sequenced, which makes them both unsuita-
ble and slow for MMAs development. 
As IEC 62304 describes only the software lifecycle processes, additional processes 
are required when the software developed forms the complete MD. In such cases 
systems development processes need also to be considered. These systems devel-
opment processes were derived from ISO/IEC 12207:2008 [22]. Quality Management 
and Risk Management related requirements from ISO 13485 and ISO 14971 were 
also added to MDevSPICE® as both ISO 13485 and ISO 14971 are de facto stand-
ards for MD software development organizations. MDevSPICE® consists of 23 pro-
cesses, see table 1. Ten are system lifecycle processes, eight are software lifecycle 
processes and five support both the system and lifecycle processes. 
MDevSPICE® was validated through both international expert review and industrial 
trials. The foundation of MDevSPICE® is IEC TR 80002-3, the Process Reference 
Model for IEC 62304 [23]. Upon successful completion of international expert re-
views, MDevSPICE® was validated through pilot assessments in 10 MD software de-
velopment organizations over two years. 
MDevSPICE® provides full lifecycle coverage in a plan-driven manner describing the 
requirements of all associated MD standards in one place, integrating software engi-
neering best practices so that safer MD software may be developed.  
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However, the emergence of MMAs presents a new challenge to the development of 
MD software is with. 
4 Approach used to understand the needs for Mobile Medical App 
Development Framework  
The research questions we were exploring are: 
• What are the challenges associated with development of MMA software? 
• What are the criteria/features developers would like to see within MMA develop-
ment software framework? 
• What are the existing software development approaches for developing MMA 
software? 
To answer these questions, we performed a workshop that included the experts from 
the MD community. The Oxford dictionary defines a workshop as “a meeting at which 
a group of people engage in intensive discussion and activity on a particular subject 
or project” [24]. An action research methodology consists of five phases: diagnosing, 
action planning, action taking, evaluating and specifying learning [25] and will be de-
scribed in more detail in the following subsections. In the development of the MMA 
framework the research methodology adopted is action research and the workshop 
formed a key part for the diagnosing stage. 
4.1 Mobile Medical App Development Framework Workshop 
In order to be able to run a truly scientific workshop we approached 37 organizations 
that develop either MD or MMA software. The Regulated Software Research Centre 
(RSRC) maintains a repository of contact details of MD software experts within Ire-
land and this was used as the basis for identifying suitable organizations. The selec-
tion process then consisted of inviting representatives (from this repository) from mul-
tinational and SMEs MD software communities within Ireland. 
Fifteen (41%) of the invited organizations sent at least one representative, resulting in 
a total of 23 representatives. We ran two workshops in two different locations, Dun-
dalk (North of Ireland) and Limerick (South of Ireland) in order to cover the geograph-
ical spread, see table 2. 
A structured invitation template explaining the objective of the workshop and location 
was developed along with a separate word document detailing the agenda that ex-
plained the workshop structure. These details were sent to chosen experts approxi-
mately a month prior to the first workshop. After sending invitations, a reminder email 
was sent one week prior to the first workshop, followed by an email to the confirmed 
representatives detailing location (including a map and the conference room num-
ber). Both workshops were run in academic institutes – Dundalk Institute of Technol-
ogy and the University of Limerick; we discussed the changing face of MD software 
and the associated standards, and regulations that organizations need to be aware of 
today. We also looked at the current MMA software development approaches and 
discussed the challenges when developing mobile medical applications. Then, we 
had a session discussing the awareness levels of agile for MMA software develop-
ment and we concluded the workshop with suggestions with what should be included 
in a MMA development framework. 
4.2 Mobile Medical Application Development Challenges 
One of the discussion topics within the workshop was: What are the challenges as-
sociated with developing MMA software? Participants were divided into groups of 4-5 
people from different companies and were allocated 20 minutes for discussion. At the 
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end of this discussion, group leaders were asked to preset the list of MMA dev chal-
lenges on a flipchart. Once all challenges were reported back, an overall discussion 
took place to enable us to arrive at the final agreed list of challenges which are 
shown in Table 3. 
4.3  Mobile Medical App Development Framework Features 
Our second workshop discussion related to the following question: What are the crite-
ria/features developers would like to see within a MMA development software frame-
work? This discussion was run in the same manner as outlined in Section 4.2. 
We discovered that there is a necessity to develop regulatory compliant applications 
in a shorter timeframe than traditional MD software. Figure 1, represents the features 
that experts felt should be included into a MMA development framework. As illustrat-
ed in figure 1, the most highly desired features were regulatory requirements, the 
need for documentation to satisfy these requirements through objective evidence and 
traceability. 
 
 
 
Figure 1 Mobile Medical App Development Framework Features 
 
In order to be able to market a MMA, it is essential to achieve regulatory compliance. 
This involves providing fully traceable documentation that forms the objective evi-
dence required by the auditors. Therefore, it is understandable that these features: 
documentation, adaption to regulatory requirements, knowledge of regulations and 
traceability were the most sought after from the MD software experts that participated 
in the workshop. However, time to market is also important and it is a key distinguish-
ing factor between the development of traditional MD software and the development 
of a MMAs. 
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The workshop outlined that the mentioned features could be achieved through a hy-
brid development approach when agile practices were integrated into a plan driven 
software development approach such as the V-model. 
4.4 Approaches 
Our third workshop discussion related to the following question: What are the existing 
software development approaches for developing MMA software? This discussion 
was conducted as outlined in Section 4.2. 
Generally, in the MD software industry the V-model is adopted. However, due to suc-
cesses reported within other domains from implementing agile practices, an interna-
tional working group was set up to investigate if agile practices could fulfil the re-
quirements of IEC 62304. The Association for the Advancement for Medical Instru-
mentation (AAMI) working group found that “agile practices can be successfully 
adopted to develop regulatory compliant software” [26] and produced AAMI:TIR 
45:2012 [27] which is an internationally accepted technical report called “Guidance 
on the use of Agile practices in the development of medical device software”. 
AAMI:TIR 45 provides general guidelines on how agile methods may be used to sat-
isfy IEC 62304. To obtain a suitable development lifecycle for MMAs we have com-
pared various potential MD software development approaches before deciding to de-
velop a MMA framework where agile practices are combined with MDevSPICE® while 
observing the guidelines of AAMI:TIR 45. 
As part of the workshop we presented six possible Software Development Life Cycle 
(SDLC) approaches that are used for developing MMAs. Based upon the two previ-
ous group discussions concerning MMA development challenges and identifying 
MMA development framework features, it was agreed by participants to categorize 
each SDLC approach in terms of the following criteria: a) achieving regulatory com-
pliance and producing the required documentation; and b) time to market – does the 
approach assist the MD to be marketed in a timely manner (see Table 2).  In the fol-
lowing section we outline the discussion surrounding each software development ap-
proach. 
4.4.1 Waterfall or V-model  
The intention of plan-driven software development methods is to improve the product 
quality by reducing the number of errors that are made, while at the same time sup-
porting the achievement of delivery dates, budget constraints and in the case of MD 
software development the achievement of the primary goals of creating safe and ef-
fective MDs. MD software developers typically develop software in accordance with a 
plan-driven sequential SDLC, such as the V-Model or Waterfall [28], as it is a tried 
and trusted lifecycle approach within the industry for producing the deliverables de-
manded by the regulatory authorities [29], [30]. However, participants agreed that this 
is a time consuming, resource-intensive and rigid plan-driven approach that is not 
well suited for developing MMAs in a timely manner. 
The group discussion identified several concerns with adopting either a waterfall or 
V-Model SDLC adoption, such as: there is no focus upon iterations, consequently, 
making it difficult to deliver frequent releases and to change incorrect decisions in a 
timely manner; they do not embrace change easily, thus, any changes introduced 
once the project has started can create financial overruns; they do not include a pro-
totyping practice, therefore making it more difficult to  engage users in the develop-
ment process; a large amount of time is spent producing and verifying documenta-
tion, therefore leaving less time for the development and testing; there is a sign-off 
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process after every software development phase, hence, bringing an inflexibility in 
terms of incorporating changes post sign-off. 
In traditional MD development there is a heavy emphasis on documentation and sign-
off before proceeding to the next stage. This can lead to delays when changes need 
to take place. Such development lifecycles are waterfall in nature with each stage 
having to be completed prior to the next commencing. Therefore, the key concern in 
relation to this approach is that delivering working software may take a long time. 
4.4.2 MDevSPICE®  
Similarly, to MD software standards, MDevSPICE® doesn’t specify the development 
method that should be used in the design and development of MD software. Yet, giv-
en the fact that the following are required for MD regulatory approval: a defined pro-
cess description; sign-off on all tasks and requirements; and documented evidence of 
these, this suggests that either a waterfall or V-model lifecycle approach is well suit-
ed.  
Participants felt, that a significant advantage of MDevSPICE® is that the software 
processes necessary to satisfy regulatory requirements are identified from the outset 
and implemented accordingly. While this approach involves the production of a lot of 
documentation, it streamlines the identification of appropriate software development 
practices. It was decided by participants that despite MDevSPICE® streamlining the 
procedure for obtaining regulatory compliance and generating the required documen-
tation, a plan driven implementation is still time-consuming and resource-intensive. 
Participants felt, that increased agility permits a more rapid adaptation to changing 
requirements and allows early detection of errors through prototyping, which fits the 
MMA development better than plan-driven methods. 
4.4.3 Introducing Agile Practices into the V-model Lifecycle (not based on 
MDevSPICE®) 
“Agile development focuses on achieving personal, technical, and organizational 
successes” [31]. Agile software development reports “the promise of improved soft-
ware quality and reduced delivery times” [32]. There are several reported benefits for 
adopting agile development practices including: more rapid feedback and adjusting 
and embracing change accordingly; producing frequent releases of working software; 
and reducing formal organisational red tape.  
An agile approach for software development for MDs goes back to the 2000s, and in 
2005 Sutherland evaluated Scrum, which is an agile project management approach, 
by using a medical company [33]. Scrum is currently implemented in several MD 
software development companies [34], [35], [36], [37]. Scrum is widely used due to its 
clear roadmap; its structure is easy to understand and to implement. However, Scrum 
is only one part of the solution as it focuses on project management and collabora-
tion by concentrating on business value through demonstration and prioritization. 
Therefore, eXtreme Programming (XP) can be used in conjunction with Scrum [2]. 
Case studies [38], [39], [40], [34] have emphasized that following an agile approach 
can overcome the issues associated with plan driven software development [41]. 
Participants felt, that by integrating agile practices into the V-model development 
lifecycle it provides the advantage of accommodating changes more easily than the 
previous two approaches. However, it was also felt as this approach is not based on 
MDevSPICE®, there is an overhead on ensuring that all the regulatory practices with 
the necessary documentation are in place. McHugh et al. [26] found that by integrat-
ing agile practices into the V-model to streamline requirements changes, the amount 
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of rework required is reduced and delivering MD software is achieved in a more time-
ly manner. 
4.4.4 Integrating Agile Practices into the V-model (based upon MDevSPICE®) 
Alongside with benefits and barriers that an agile approach brings, there are also 
some challenges, such as, the need for appropriate tool support for generating doc-
umented evidence of all iterations; a proper level of traceability, risk mitigation, verifi-
cation and validation of the processes; and the need to provide detailed documenta-
tion (e.g., detailed test steps [40]). 
This approach is based upon MDevSPICE® and includes agile practices that may be 
used to fulfil the requirements defined in the framework. Participants thought that this 
approach assists companies to ensure that they have all the necessary standards in 
place including all the documentation gathered during all stages of the lifecycle. 
However, participants felt, that there is still a challenge in relation to determining how 
to capture this documentation when integrating agile practices. This approach sup-
ports getting the product to the market faster than the previous approach as guidance 
is provided to assist organizations to put the required standards in place. 
4.4.5 Integrating Agile Practices into Reduced V-model (not based on 
MDevSPICE®) 
This approach looks to integrate agile practices into a reduced V-model lifecycle that 
only includes essential activities for MMA development. The participant group found 
that by not integrating MDevSPICE®, additional attention is required in order to en-
sure that adequate coverage of standards is in place within the implemented agile 
practices. It was felt that as this approach is light on documentation; extra attention 
should be paid in terms of what documentation is required for regulatory compliance. 
Participants thought, that whilst agile practices allow working MMA software to be 
delivered faster, the process of implementing one standard at a time will slow the 
process down significantly. 
4.4.6 Integrating Agile Practices into Reduced V-model (based upon 
MDevSPICE®) 
This approach is similar to the previous approach except it is based upon 
MDevSPICE®. This streamlines the process overhead of ensuring that implemented 
agile practices satisfy all the required MD guidelines and also reduces the implemen-
tation time requirement. The authors proposed to create a mapping of the most appli-
cable agile practices within the SDLC against the complete MDevSPICE®. Then, 
populate the reduced V-model that is based on MDevSPICE® with the most suitable 
agile practices to fulfil the minimum set of requirements for MMA development. This 
approach is light on documentation, only including the most essential documents to 
satisfy the regulatory requirements. Crucially, it was felt by participants, that by 
adopting this approach, MMA software will reach the market faster than the other ap-
proaches as developers are only focused on essential activities, with regulatory com-
pliance being achieved seamlessly during development. 
The conclusion from this discussion was that “integrating agile practices into reduced 
V-model” was considered to be the best MMA development approach for the work-
shop group participants. 
The next section is going to discuss one of the key criteria identified in the discussion 
on features for inclusion in a MMA development framework which is traceability. 
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5 Traceability 
Traceability is the ability to establish and use the links (or traces) between source 
artefacts and target artefacts [42] and it is important as developers need to ensure 
that their software conforms to customer expectations, functional and regulatory re-
quirements. Furthermore, organizations that produce safety critical software, such as 
those operating within the MD domain, must ensure their software is safe, reliable 
and available. Traceability is an important component in ensuring safe and reliable 
software and is a required component of the approval and certification process [43] 
which requires that safety critical software is certified before entering service. Moreo-
ver, as noted above, traceability is a highly desired feature for MMA development 
framework. 
As in other domains, traceability implementation within the MD domain is challenging 
and has been highlighted by a recent analysis of the traceability documents submit-
ted to regulators in the US as part of the MD approval process. This analysis has re-
vealed that the traceability data was incomplete, incorrect, and conflicting in many 
cases [43]. 
Therefore, to assist MD software organizations implement traceability effectively the 
authors have developed a traceability assessment and implementation framework 
(TAIF). The TAIF consists of a traceability assessment model (TAM) and a traceabil-
ity roadmap (TR). The TAM allows for the identification of any weaknesses in an or-
ganizations existing traceability process and the TR provides the pathway for an or-
ganization to address those weaknesses. We define a traceability roadmap as a set 
of steps or activities that, if followed, will provide guidance to an organization imple-
menting traceability, and ensure that it is compliant with the traceability requirements 
from the MD standards and traceability implementation best practices.  
An overview of the approach employed to develop the TAM and its structure is pre-
sented in section 5.1. Further detail on the structure of the TAM can be obtained in 
[44, 45]. Section 5.2 presents an overview of the approach used to develop the TR 
along with its structure. Further detail on the structure of the roadmap can be ob-
tained in [46]. Section 5.3 provides an outline of the approach employed to validate 
the TAIF in addition to a summary of the findings from implementing the TAIF within 
two MD software organizations. 
5.1 TAM Development and Structure 
It was decided to base the development of the TAM on the ISO/IEC 15504 (SPICE) 
assessment model mainly because ISO/IEC 15504 is used extensively in other safety 
critical industries such as the automotive industry (Automotive SPICE), space 
industry (SPICE 4 SPACE) and the MD industry (MDevSPICE). 
Having decided to base the TAM on IS/IEC 15504, an approach to its development 
was formulated as depicted in Figure 2. 
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Figure 2 TAM Development Approach 
A Process Assessment Model (PAM), as defined in ISO/IEC 15504, is based on a 
two dimensional model containing a process dimension and a capability dimension. 
The process dimension is provided by aal Process Reference Model (PRM), which 
defines a set of processes characterized by statements of process purpose and 
process outcomes.  
The development of the PRM began with an analysis of the MD standards in order to 
extract the traceability requirements within those standards. The standards analyzed 
were: ISO 13485; IEC 62304; ISO 14971; IEC 80002-1; IEC 60601-1; and the FDA 
guidance documents on MD software development which includes the guidance doc-
ument on the development of MMAs. This analysis resulted in twenty-four traceability 
requirements. Additionally, as the aim of this study is to develop a TAIF which will 
assist with the implementation of the standards’ requirements for traceability along 
with the best practices for implementing traceability, the twenty-three best practices 
identified during a literature review were included in the PRM [47].  
To establish a uniformity of description of the processes in this TAM, technical report 
ISO/IEC TR 24774 (ISO/IEC, 2010) was employed. This report provides guidelines 
for process description. 
Section 6.2 of ISO/IEC 15504-2 sets out the minimum requirements for a PRM. The-
se requirements state that the process descriptions incorporate a statement of the 
purpose of the process together with the set of outcomes which demonstrate suc-
cessful achievement of the process purpose. 
While ISO/IEC 15504-2 details the minimum requirements that a PRM and a PAM 
should meet, it provides no guidance on how to develop the models i.e. it does not 
tell you how to transform a set of requirements into a PRM or PAM. To address this, 
issue the Tudor IT Service Management Process Assessment (TIPA) transformation 
process [48] was employed as it complies with the requirements for PRMs and PAMs 
as expressed in ISO/IEC 15504-2. 
The TAM contains the following four traceability processes: SDLC traceability pro-
cess; Risk management traceability process; Change management traceability pro-
cess; and a Traceability implementation best practices process.  In accordance with 
ISO 15504, each of the four processes in this TAM contain a process description and 
a set of indicators, known as base practices and work products. Base practices pro-
vide a definition of the tasks and activities needed to accomplish the process purpose 
and fulfil the process outcomes. Evidence of performance of the base practices, and 
the presence of work products provide objective evidence of the achievement of the 
purpose of the process. 
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5.2 Roadmap Development and Format  
The approach employed to develop the TR is depicted in Figure . 
 
 
Figure 3: Roadmap Development Approach 
A method proposed in [49] provides a systematic approach to roadmap construction. 
The first three steps of this method involved identifying traceability requirements from 
the standards, grouping the requirements into goals and then separating the goals in 
line with ISO/IEC 15504 capability levels. To develop the roadmap, it was not neces-
sary to complete these steps as they had already been completed as part of the de-
velopment of the TAM. The grouped goals or milestones identified in the above pro-
cess are equivalent to the grouped goals contained within the TAM and so a mile-
stone equates to a TAM process. 
 The fourth step involved ordering the milestones based on the capability level and 
logical groups. The four processes within the TAM are all at capability level 1 and so 
conferred no order priority. Thus the processes were arranged in the order in which 
they should be implemented within a development project. This order consists of the 
best practices being implemented before development begins. Then the RM trace 
process and CM trace process are to be implemented concurrently with the SDLC 
trace process. 
Steps 5 and 6 consisted of validating the generated roadmap (by industry experts) 
and identifying activities that can meet the identified goals. It was considered to be 
more productive to alternate these two steps as the TAM processes had already 
been validated by expert review during the development of the TAM. Therefore, activ-
ities were identified before the roadmap was referred for initial validation by expert 
review. These activities are labelled as base practices in the roadmap, with each 
base practice containing two exemplar methods of how to implement them. For the 
final step the traceability roadmap underwent industry validation by implementation in 
two medicals device software organisations.  
A literature review on roadmaps revealed a taxonomy of eight roadmap types in 
terms of purpose, and eight roadmap formats in terms of graphical representation 
[50]. It was considered that the traceability roadmap would better align with the ‘Pro-
cess planning’ type of roadmap. This type supports the management of knowledge, 
focusing on a particular process area. In the case of the traceability roadmap the fo-
cus is on knowledge flows that are needed to facilitate effective traceability imple-
mentation. In addition to, and perhaps more important than roadmap type, the format 
of the roadmap was then considered. It was decided that the roadmap should be a 
hybrid version entailing mainly ‘single layer’ and ‘text’ formats, with some pictorial 
representation. The pictorial representation is presented early in the roadmap to give 
the user an overview whereas text is used to describe the roadmap in detail. This hy-
brid version was chosen for the following reasons: 
Roadmap Types 
and Formats 
(Phaal 2003) 
Traceability 
Roadmap 
Roadmap Devel-
opment Methodology 
Flood (2014) 
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• Combinations of pictorial and text information facilitate significant improve-
ments in understanding [51]; 
• The single layer roadmap is a subset of the multilayer format and is less com-
plex. A pictorial representation can present a lot of information in a readily un-
derstandable format. 
5.3 TAIF Validation 
The approach taken to validating the TAIF is presented in Figure 4. The validation is 
completed in two stages. The first stage is an initial validation by expert review while 
the second stage is further validation by implementation of the TAIF in two MD organ-
izations. 
 
 
Figure 4: TAIF Validation Approach 
5.3.1 Initial Validation 
An initial validation of the TAIF was completed through expert review [45, 46]. Thir-
teen international experts in areas such as ISO/IEC 15504, MD software develop-
ment and processes, MD software standards, traceability research and implementa-
tion, software process improvement, and roadmap development. This validation en-
tailed the experts being asked to review the models and then to complete a ques-
tionnaire about the models. The questionnaire was composed of questions relating to 
the usefulness, usability and content of the models and asked for suggestions for im-
provement. After the questionnaires were returned, a focus group was formed to 
consider all the responses and through general consensus decisions were taken as 
to what changes should be made to the models. After the changes were made the 
models were now ready for industry trial. 
5.3.2  Approach to Industry Validation  
To further validate the TAIF a longitudinal study of two MD organizations was per-
formed over a six-month period. An initial assessment was conducted to assess the 
organisations’ implementation of traceability requirements and best practices. One 
week later a report was presented to both organisations detailing their traceability 
weaknesses, along with a roadmap which provided recommendations on how they 
could address those weaknesses. After a six-month period a follow up assessment 
was conducted. This follow up assessment ascertained if any improvement had been 
made. Additionally, the follow up assessment ascertained each organisation’s per-
spective of the assessment experience and of the roadmap. 
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To collect the relevant data a mixture of interviews and document reviews were em-
ployed. Interview questions to ascertain the current implementation of traceability re-
quirements and best practices were developed based on the TAM base practices. To 
determine the organisation’s perspectives of the assessment experience and the 
roadmap, questions were formulated which assessed their value, usefulness, and 
usability to the organisations. A semi-structured interview was developed based on 
the interview guide development strategy championed by [52]. The interview con-
tained a mixture of both open and closed questions. The closed questions ensured 
that very specific and required data was collected e.g. the organisations implementa-
tion of specific traceability requirements. The open questions allowed for the inter-
viewees to reflect and give their opinion on the value, usefulness and usability of the 
assessment experience and the roadmap.  These questions were then independently 
reviewed by two persons with extensive experience in developing interview guides.  
To introduce and implement the TAIF to both organisations the Adept method [53] 
was employed. The Adept method was used as it could provide a comprehensive 
assessment of an organizations’ traceability compliance without being too onerous in 
terms of resources that the organization needs to provide. In addition, the Adept 
method also includes a follow up study to evaluate how well the implementation of 
the recommended changes was performed allowing for a full evaluation of not only 
the assessment model but also the roadmap. 
5.3.3 Sample Size and Participants 
This study was conducted in two MD organizations. The main factors which directly 
influenced the sample size for this study were;  
1) Resources in terms of time and cost.  
2) Perceived requirement. The authors considered this study has a narrow topic and 
uses in depth interviews which will limit the number of participants needed. Addi-
tionally, the general population of MD software SMEs in Ireland is approximately 
fifty which again limits the number of participating organisations required.  
The two participating organizations were chosen on the basis that the researcher was 
able to get personal introductions to management within these organizations. Two 
individuals from each organization participated in the interviews. These individuals 
best understood each organizations traceability process and were selected by the 
organization themselves.  
The first organization that agreed to participate in the study, Organization A, is a 
small MD software company, founded in 2002, based in Ireland. The company has a 
total of ten employees which include one programmer, one software tester and one 
quality assurance person. The company produces MD software with a software safe-
ty classification of B, meaning non-serious injury is possible. 
The second company, Organization B is a small Product Development & Design En-
gineering company focused on the MD and Life Science market and is based in Ire-
land. The company, which was formed in 2007, employs 14 individuals with skills in 
mechanical, hardware and software engineering. The company are a third party sup-
plier of software to MD companies and have recently been accredited with IEC 62304 
certification. 
5.3.4 Data Analysis 
The interviews, which were recorded by Dictaphone, were transcribed into Microsoft 
word documents. Additionally, notes were made during the interview. Due to the 
open ended nature of part of the interview guide, the data generated consisted of 
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long paragraphs with similar concepts in different locations of the text and with data 
unrelated to the study. This data was considered to be unstructured and so qualita-
tive content analysis, using deductive and inductive coding, was used to structure the 
data into meaningful and analyzable data from which conclusions could be drawn.  
Categories and codes based on the purpose of the interview questions were estab-
lished prior to coding (deductive). Annotating the text involved carefully reading the 
text a number of times, each time underlining the text that applied to any category 
and annotating the underlined text with the category code. While carrying out this 
process a number of new categories emerged (inductive). This process was repeated 
until no new text for coding emerged. 
5.3.5 Implementation Findings   
A comparison of the initial and follow-up assessments indicates that both organiza-
tions had significantly improved almost all traceability processes, although none of 
the processes improved to a level of 100% adherence. The overriding reason given 
for this is resource issues (mostly time) within the organizations. These resource is-
sues are clearly outside the scope of the TAIF.  
An evaluation of the assessment experience and traceability roadmap clearly indi-
cates that both organizations found them to be very useful, usable and generally 
providing an awareness, knowledge and expertise in traceability that they did not 
previously have. Additionally, both organizations considered that the assessment 
provided them with guidance and real direction for long term traceability improve-
ment.  
Further detail on the findings can be obtained in [54]. 
6 Conclusion and Future Work 
This journal paper described our approach for a MMA development framework. In 
order to ensure that the framework addressed the true needs of the MMA 
development community we conducted a workshop with the experts within the MD 
software domain. Within this workshop there was three discussion areas. The first of 
these areas concerned challenges within MMA development. The second area of 
discussion concerned the features that should be included within a MMA framework 
to overcome the challenges mentioned in first discussion. The final discussion 
concerned the actual software development approach for the MMA framework where 
we looked at six different software development lifecycles.  
Whilst the MMA framework will contain many features that were identified within the 
workshop by experts, due to space restrictions we have provided an examplar of one 
of these features – traceability. We described the development and validation of the 
traceability component of the MMA framework. 
In the future, we plan to develop the complete MMA framework to include all of the 
features identified in Section 4.3. Upon completion of this MMA framework we plan to 
validate it within the organizations that participated in the workshop. Another area we 
wish to focus upon is the development of an agile approach for MDevSPICE® that 
can be used for both MMAs and general MD software development. This work will be 
validated both within the agile and MD standards communities and the MD software 
industry.  
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Table 1. MDevSPICE® Processes 
Medical Device System 
Lifecycle Processes 
Medical Device Software 
Lifecycle Processes 
Medical Device 
Support Pro-
cesses 
Project Management 
Risk Management 
Stakeholder Requirements Defini-
tion 
Project Assessment and Control 
System Requirements Analysis 
System Architecture Design 
System Integration 
System Qualification Testing 
Software Installation 
Software Acceptance Support 
Software Development Planning 
Software Requirements Analysis 
Software Architecture Design 
Software Detailed Design 
Software Risk Management 
Software Unit Implementation 
and Verification 
Software Integration and Integra-
tion Testing 
Software System Testing 
Configuration 
Management 
Software Release 
Software Problem 
Resolution 
Software Change 
Request Man-
agement 
Software Mainte-
nance 
 
 
Table 2. Workshop attendance figures 
Location Attendees Organizations 
Dundalk 13 9 
Limerick 10 6 
Total 23 15 
 
 
Table 3. MMA development challenges in A-Z order 
 
• Adoption/Uptake 
• Architecture 
• Automated testing tools 
• Best available development toolset 
• Connectivity, security and the valida-
tion of them 
• Data flow 
• Dependency on OS, hardware and 
network 
• Development lifecycle and app distri-
bution 
• Hardware/Platform eg., Phone/Tablet, 
• Overhead of adopting required 
standards and compliance 
• Platform selection and valida-
tion 
• Providing essential updates 
when offline 
• Release and version man-
agement 
• Synchronisation between dif-
ferent devices for apps 
• Time to market 
• Understanding what SOUP is 
Page 19 of 24
http://mc.manuscriptcentral.com/jsme
Journal of Software: Evolution and Process
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
iOS/Android  
• Knowing if app is a component or a 
complete MD 
• Usability and Testing on differ-
ent versions of app hardware 
and platforms 
 
 
Table 4. Model Comparison 
Software Development 
Lifecycle 
Regulatory Compliance and 
Documentation 
Time to Market 
Waterfall or V-model One standard at a time – 
very lengthy process 
Very slow; Re-
source intensive 
MDevSPICE® (waterfall or 
V-model) 
Shorter process – all stand-
ards easily put in place 
Slow; Resource in-
tensive 
V-model with agile practic-
es 
One standard at a time; 
Challenge with documentation 
Bit faster; Full 
lifecycle covered 
V-model with agile practic-
es & MDevSPICE® 
All standards easily put in 
place; Challenge with docu-
mentation 
Faster and all 
standards are cov-
ered 
Reduced V-Model with ag-
ile practices 
One standard at a time; 
Challenge with documentation 
Faster; Focused on 
essential activities 
Reduced V-Model with ag-
ile practices & MDevSPICE® 
All standards easily put in 
place; Challenge with docu-
mentation 
Faster; Focused on 
essential activities 
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Figure 1 Mobile Medical App Development Framework Features  
Figure 1  
127x79mm (600 x 600 DPI)  
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Figure 2 TAM Development Approach  
Figure 2  
14x8mm (600 x 600 DPI)  
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Figure 3: Roadmap Development Approach  
Figure 3  
4x1mm (600 x 600 DPI)  
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Figure 4: TAIF Validation Approach  
Figure 4  
7x4mm (600 x 600 DPI)  
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